ARWR
Price
$16.08
Change
+$0.01 (+0.06%)
Updated
Jun 27 closing price
Capitalization
2.22B
43 days until earnings call
SKYE
Price
$4.11
Change
-$0.14 (-3.29%)
Updated
Jun 27 closing price
Capitalization
128.62M
Interact to see
Advertisement

ARWR vs SKYE

Header iconARWR vs SKYE Comparison
Open Charts ARWR vs SKYEBanner chart's image
Arrowhead Pharmaceuticals
Price$16.08
Change+$0.01 (+0.06%)
Volume$2.08M
Capitalization2.22B
Skye Bioscience
Price$4.11
Change-$0.14 (-3.29%)
Volume$7.49M
Capitalization128.62M
ARWR vs SKYE Comparison Chart in %
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. SKYE commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Buy and SKYE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (ARWR: $16.08 vs. SKYE: $4.11)
Brand notoriety: ARWR: Notable vs. SKYE: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 129% vs. SKYE: 811%
Market capitalization -- ARWR: $2.22B vs. SKYE: $128.62M
ARWR [@Biotechnology] is valued at $2.22B. SKYE’s [@Biotechnology] market capitalization is $128.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileSKYE’s FA Score has 0 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • SKYE’s FA Score: 0 green, 5 red.
According to our system of comparison, SKYE is a better buy in the long-term than ARWR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 3 TA indicator(s) are bullish while SKYE’s TA Score has 4 bullish TA indicator(s).

  • ARWR’s TA Score: 3 bullish, 4 bearish.
  • SKYE’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, SKYE is a better buy in the short-term than ARWR.

Price Growth

ARWR (@Biotechnology) experienced а +4.96% price change this week, while SKYE (@Biotechnology) price change was +90.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ARWR is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($2.22B) has a higher market cap than SKYE($129M). SKYE YTD gains are higher at: 45.230 vs. ARWR (-14.468). SKYE has higher annual earnings (EBITDA): -31.66M vs. ARWR (-68.12M). ARWR has more cash in the bank: 1.1B vs. SKYE (59.2M). SKYE has less debt than ARWR: SKYE (412K) vs ARWR (388M). ARWR has higher revenues than SKYE: ARWR (545M) vs SKYE (0).
ARWRSKYEARWR / SKYE
Capitalization2.22B129M1,722%
EBITDA-68.12M-31.66M215%
Gain YTD-14.46845.230-32%
P/E RatioN/A3.57-
Revenue545M0-
Total Cash1.1B59.2M1,853%
Total Debt388M412K94,175%
FUNDAMENTALS RATINGS
ARWR vs SKYE: Fundamental Ratings
ARWR
SKYE
OUTLOOK RATING
1..100
7640
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
39
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
5935
P/E GROWTH RATING
1..100
298
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SKYE's Valuation (39) in the null industry is somewhat better than the same rating for ARWR (94) in the Biotechnology industry. This means that SKYE’s stock grew somewhat faster than ARWR’s over the last 12 months.

SKYE's Profit vs Risk Rating (100) in the null industry is in the same range as ARWR (100) in the Biotechnology industry. This means that SKYE’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's SMR Rating (96) in the Biotechnology industry is in the same range as SKYE (97) in the null industry. This means that ARWR’s stock grew similarly to SKYE’s over the last 12 months.

SKYE's Price Growth Rating (35) in the null industry is in the same range as ARWR (59) in the Biotechnology industry. This means that SKYE’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for SKYE (98) in the null industry. This means that ARWR’s stock grew significantly faster than SKYE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRSKYE
RSI
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 4 days ago
86%
Declines
ODDS (%)
Bearish Trend 13 days ago
83%
N/A
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AELTF1.10N/A
N/A
Adacel Technologies Ltd.
FOCIF2.50N/A
N/A
Focusrite Plc.
GSFD0.12N/A
N/A
Global Seafood Technologies, Inc.
HPHTF11.46N/A
N/A
Hamamatsu Photonics
TERRF9.95N/A
N/A
Terna Rete Elettrica Nazionale SPA

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
+0.06%
DNLI - ARWR
58%
Loosely correlated
-2.69%
IMNM - ARWR
55%
Loosely correlated
-0.23%
BEAM - ARWR
54%
Loosely correlated
-1.98%
RGNX - ARWR
53%
Loosely correlated
-4.11%
YMAB - ARWR
52%
Loosely correlated
-2.08%
More

SKYE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SKYE has been loosely correlated with CRBP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SKYE jumps, then CRBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SKYE
1D Price
Change %
SKYE100%
-3.29%
CRBP - SKYE
46%
Loosely correlated
-7.73%
JANX - SKYE
41%
Loosely correlated
-1.57%
OVID - SKYE
36%
Loosely correlated
-11.95%
VKTX - SKYE
34%
Loosely correlated
-5.86%
ARWR - SKYE
33%
Loosely correlated
+0.06%
More